Daiichi Sankyo Executive and Leadership Team

Kazuki Mori, the Chief of Staff To Chief Executive Officer at Daiichi Sankyo, coordinates strategic initiatives and streamlines communication between the executive office and global business units. Facilitating high-level decision-making processes, the Chief of Staff To Chief Executive Officer manages the daily operational agenda to ensure alignment with the company's pharmaceutical mission. Kazuki Mori synthesizes complex data from various departments to provide actionable insights for the Chief Executive Officer. This role involves overseeing cross-functional projects that impact the company's market position in over 30 countries. By optimizing internal workflows, the Chief of Staff To Chief Executive Officer enhances organizational efficiency and supports the rapid deployment of new drug delivery methods. Mori maintains rigorous standards for project execution and strategic planning. Through constant engagement with senior leadership, the Chief of Staff To Chief Executive Officer drives the implementation of corporate goals and ensures the seamless execution of long-term growth strategies.

Hiroyuki Okuzawa, the Chief Financial Officer at Daiichi Sankyo, directs all global fiscal operations and capital allocation strategies. Managing the financial health of this pharmaceutical enterprise, the Chief Financial Officer oversees long-term investment portfolios and ensures robust funding for advanced drug discovery initiatives. By analyzing market trends across diverse international regions, Okuzawa optimizes resource distribution to support the development of innovative medicines. This leadership role involves close collaboration with the Board to maintain fiscal transparency and drive sustainable growth. Hiroyuki Okuzawa monitors quarterly performance metrics to align departmental spending with the overarching corporate mission of improving patient outcomes. Through precise financial modeling and risk assessment, the Chief Financial Officer secures the necessary capital to expand the company's footprint in competitive global markets. Ultimately, Okuzawa strengthens the balance sheet to facilitate continuous research and development breakthroughs.

Chloe Stern, the Manager, Chief Financial Officer Planning Department at Daiichi Sankyo, architects detailed financial roadmaps and budgetary frameworks for the organization. Overseeing the planning department, the Manager, Chief Financial Officer Planning Department translates high-level fiscal goals into granular operational targets. Chloe Stern analyzes pharmaceutical market dynamics to forecast revenue streams and identify potential cost-saving opportunities across global operations. This leadership role requires constant interaction with the finance team to ensure accurate reporting and strategic resource allocation. By monitoring the financial performance of specific drug development programs, the Manager, Chief Financial Officer Planning Department supports the company's commitment to innovation. Stern implements rigorous analytical tools to track departmental progress against annual objectives. Through meticulous planning and data-driven oversight, the Manager, Chief Financial Officer Planning Department ensures the financial stability required to sustain the company's extensive research pipeline and maintain a competitive edge in the global pharmaceutical industry.

Suthas Thongprasert, the President at Daiichi Sankyo, leads the overall strategic direction and operational execution of the global pharmaceutical business. Defining the corporate vision, the President drives the development of innovative medicines and the expansion of drug discovery capabilities. Suthas Thongprasert oversees the company's market presence across diverse regions, ensuring that the organization meets the needs of patients in over 30 countries. This leadership role involves setting high-level performance standards and fostering a culture of excellence within the pharmaceutical manufacturing sector. By engaging with the Board and executive team, the President ensures that all business activities align with the company's mission of improving global health. Thongprasert monitors competitive dynamics to maintain the company's position as a leader in drug delivery methods. Through decisive leadership and strategic foresight, the President secures the company's future growth and reinforces its commitment to providing high-quality, innovative healthcare solutions to the global community.

Caitlin Barnabo, the Global Oncology Medical Affairs Chief of Staff at Daiichi Sankyo, manages the operational infrastructure for the company's oncology division. Coordinating medical affairs activities across international regions, the Global Oncology Medical Affairs Chief of Staff ensures that clinical data and therapeutic insights reach healthcare providers effectively. Caitlin Barnabo aligns the oncology strategy with the broader pharmaceutical mission to deliver innovative cancer treatments to patients worldwide. This role involves facilitating collaboration between research teams and medical experts to accelerate the adoption of new drug therapies. By streamlining internal processes, the Global Oncology Medical Affairs Chief of Staff enhances the impact of clinical trials and medical education programs. Barnabo monitors the progress of oncology initiatives to ensure compliance with global standards and corporate objectives. Through strategic coordination and operational oversight, the Global Oncology Medical Affairs Chief of Staff drives the successful integration of advanced oncology solutions into the global healthcare market.

Kosuke Itagaki, the Chief of Staff & Global System Owner at Daiichi Sankyo, directs the integration of enterprise-wide digital systems and operational protocols. Serving as the primary architect for global infrastructure, the Chief of Staff & Global System Owner ensures that technological platforms support the company's pharmaceutical research and distribution needs. Kosuke Itagaki oversees the implementation of advanced data management tools to improve efficiency across all international branches. This leadership role involves coordinating with IT and operations teams to maintain system integrity and security. By optimizing the digital environment, the Chief of Staff & Global System Owner facilitates seamless collaboration between global research centers and manufacturing facilities. Itagaki monitors system performance to ensure alignment with the company's long-term growth strategy. Through rigorous oversight of global systems, the Chief of Staff & Global System Owner provides the technological foundation necessary for the company to deliver innovative medicines to patients in over 30 countries.